Applied Biosystems, part of Life Technologies Corporation
(NASDAQ:LIFE), today announced the publication of a paper in the journal
Nature that demonstrates the power of next-generation DNA sequencing
used to identify DNA mutations in a small cell lung cancer (SCLC) line
and identify the mutational burden associated with tobacco smoking. The
paper, authored by researchers from the Wellcome
Trust Cancer Institute and co-authored by Applied Biosystems,
demonstrates the potential for next-generation sequencing to provide
unprecedented insights into mutational processes, cellular repair
pathways and gene networks associated with cancer development.
“The publication of this paper emphasizes the power that next-generation
sequencing, such as Applied Biosystems’ SOLiD™
System, has to improve science’s understanding of disease and its
potential to develop better diagnostics and therapeutic treatment,” said
Kip Miller, President, Genetic Systems for Life Technologies. “Today’s
SOLiD 3 Plus System offers even more capability and is faster, more
robust and more economical than the SOLiD 2.0 System that generated the
data in the paper.”
These impactful results were generated at the Sanger Institute using an
early version of the SOLiD System. Massively parallel sequencing on
Applied Biosystems’ SOLiD 2.0 System enabled the researchers to identify
all of the mutations in the SCLC line NCI-H209 and compare them to a
matched normal cell line. Data identified several mutation signatures
that reflect the wide range of carcinogens in tobacco smoke, which is
notable because 90 percent of patients with SCLC smoked during their
lives.
Today’s SOLiD 3 Plus System is capable of generating over 60Gb of
mappable sequence at an accuracy greater than 99.95 percent.
To read the complete paper, please visit http://www.nature.com/nature/journal/vaop/ncurrent/full/nature08629.html.
Exploring the untapped potential of DNA glycosylation